Full Description
In 2010 the Institute of Medicine (IOM) recommended a framework for the evaluation of biomarkers in the chronic disease setting. Published in the book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, the framework is intended to bring consistency and transparency to the previously disparate process of biomarker evaluation.
Following the book's release, the IOM convened a 2-day discussion forum in Washington, DC, in order to provide an opportunity for stakeholders to learn about, react to, and discuss the book. Presentations reviewed the authoring committee's work process, recommendations, and provided perspectives on the book from the point of view of participants. Thomas Fleming, professor of biostatistics and statistics at the University of Washington, gave a keynote presentation on the critical issues in the validation of surrogate endpoints, a specific use of a biomarker.
The present volume recounts the discussion forum proceedings, focusing in turn on each represented sector. A summary of Dr. Fleming's presentation then sets the committee's recommendations within the context of biomarker utilization. Lastly, this summary examines the main themes raised by stakeholders, and the challenges and opportunities presented to stakeholders by the book's recommendations.
Table of Contents
Front Matter
1 Introduction
2 Committee Findings and Recommendations
3 FDA Perspectives
4 National Institutes of Health Perspectives
5 Industry Perspectives
6 Public Health, Consumer, and Consulting Organization Perspectives
7 Presentation by Thomas Fleming: Biomarkers and Surrogate Endpoints in Chronic Disease
8 Key Themes, Challenges, and Opportunities
9 Importance of the Biomarker Discussion Forum
References
Acronyms
Glossary
Appendix A: Discussion Forum Agenda
Appendix B: Summary from the Committee's Report *Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease*
Contents
1 Front Matter; 2 1 Introduction; 3 2 Committee Findings and Recommendations; 4 3 FDA Perspectives; 5 4 National Institutes of Health Perspectives; 6 5 Industry Perspectives; 7 6 Public Health, Consumer, and Consulting Organization Perspectives; 8 7 Presentation by Thomas Fleming: Biomarkers and Surrogate Endpoints in Chronic Disease; 9 8 Key Themes, Challenges, and Opportunities; 10 9 Importance of the Biomarker Discussion Forum; 11 References; 12 Acronyms; 13 Glossary; 14 Appendix A: Discussion Forum Agenda; 15 Appendix B: Summary from the Committee's Report *Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease*
